Immunomedics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Morris Plains NJ United States (1982)
Status: Acquired by Gilead Sciences (2020)

Organization Overview

First Clinical Trial
1997
NCT00003338
First Marketed Drug
2020
sacituzumab govitecan
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Immunomedics, Inc. | IMMUNOMEDICS INC